ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

ESMO Hot Topic | Professor Li Huiping: monarchE Trial OS Results Announced — A New Breakthrough in Adjuvant Therapy for HR+/HER2- High-Risk Early Breast Cancer 

At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.
CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

CSCO Experts’ Insights │ Professor Fangjian Zhou: Guideline Updates and Quality Control System Drive China’s Renal Cancer Care to the Global Forefront

From September 10 to 14, 2025, the 28th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan, Shandong. With the theme “Standardizing Diagnosis and Treatment, Leading Innovation”, the conference brought together leading domestic and international scholars. The Renal Cancer session featured the highly anticipated release of the 2025 CSCO Renal Cancer Guidelines, setting a new standard for improving treatment outcomes and promoting standardized care across China. Following the conference, Oncology Frontier – Urology Frontier invited Professor Fangjian Zhou from Sun Yat-sen University Cancer Center to discuss the groundbreaking advances in renal cancer management and the quality-control experience of the Guangdong Cancer Center.
A New Chapter in Comprehensive Management of Renal Cell Carcinoma | Professors Youyan Guan and Xiongjun Ye Provide In-Depth Insights

A New Chapter in Comprehensive Management of Renal Cell Carcinoma | Professors Youyan Guan and Xiongjun Ye Provide In-Depth Insights

On August 22–23, 2025, the 2025 Pujiang Uro-Oncology Conference was held in Shanghai, bringing together leading experts to discuss advances in urologic oncology. This article is based on the pre-conference session presented by Professor Youyan Guan (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Xiongjun Ye, titled “Comprehensive Management of Renal Cancer Patients.” Their lecture systematically reviewed the evolution of treatment concepts, perioperative and advanced-stage strategies, and the construction of comprehensive management systems, aiming to provide clinical and research colleagues with valuable reference and guidance.
Transformative Advances in mHSPC Treatment Strategies

Transformative Advances in mHSPC Treatment Strategies

Editor’s Note: On August 22–23, 2025, the highly anticipated 2025 Pujiang Uro-Oncology Conference was held in Shanghai, gathering leading experts in urologic oncology from across China and abroad. Among the key topics was the optimization of treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC). Professor Xinan Sheng from Peking University Cancer Hospital delivered an insightful lecture titled “The Combination Revolution in mHSPC — Multi-Strategy Optimization of Patient Management.” His talk provided a systematic review of the current treatment landscape, key challenges, and future directions for mHSPC management.